UBS AM
GSK icon

UBS AM’s GSK GSK Stock Holding History

UBS AM’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.12M Hold
40,423
– – ﹤0.01% 2025
2026
Q1 		$2.23M Buy
40,423
+34,519
+585% +$1.87M ﹤0.01% 1995
2025
Q4 		$290K Buy
+5,904
New +$275K ﹤0.01% 2419
2020
Q4 		– Sell
-66,640
Closed -$3.14M – 2565
2020
Q3 		$3.14M Sell
66,640
-896,744
-93% -$44.9M ﹤0.01% 1350
2020
Q2 		$49.1M Sell
963,384
-164,376
-15% -$8.43M 0.03% 488
2020
Q1 		$53.4M Buy
1,127,760
+200,960
+22% +$10.7M 0.04% 420
2019
Q4 		$54.4M Sell
926,800
-19,022
-2% -$1.06M 0.03% 508
2019
Q3 		$50.5M Buy
945,822
+803,212
+563% +$41.3M 0.03% 505
2019
Q2 		$7.13M Buy
142,610
+30,957
+28% +$1.55M 0.01% 1067
2019
Q1 		$5.83M Sell
111,653
-18,961
-15% -$947K ﹤0.01% 1093
2018
Q4 		$6.24M Buy
130,614
+4,792
+4% +$236K 0.01% 1011
2018
Q3 		$6.32M Buy
125,822
+80,393
+177% +$4.08M ﹤0.01% 1067
2018
Q2 		$2.29M Buy
45,429
+45,066
+12,415% +$2.27M ﹤0.01% 1444
2018
Q1 		$17.7K Sell
363
-274
-43% -$12.8K ﹤0.01% 2548
2017
Q4 		$28.2K Buy
637
+119
+23% +$5.5K ﹤0.01% 2463
2017
Q3 		$26.3K Hold
518
– – ﹤0.01% 2425
2017
Q2 		$27.9K Sell
518
-22
-4% -$1.17K ﹤0.01% 2406
2017
Q1 		$28.5K Sell
540
-110
-17% -$5.58K ﹤0.01% 2370
2016
Q4 		$31K Buy
+650
New +$32.1K ﹤0.01% 2334
2014
Q3 		– Sell
-3,110
Closed -$208K – 2574
2014
Q2 		$208K Buy
3,110
+14
+0.5% +$948 ﹤0.01% 2390
2014
Q1 		$207K Sell
3,096
-137
-4% -$9.26K ﹤0.01% 2404
2013
Q4 		$216K Buy
+3,233
New +$210K ﹤0.01% 2327
2013
Q3 		– Sell
-3,430
Closed -$214K – 2502
2013
Q2 		$214K Buy
+3,430
New +$218K ﹤0.01% 2236

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

UBS AM's GSK Position: Q2 2026 in Review

UBS AM held its GSK (GSK) position steady in Q2 2026 at 40,423 shares worth $2.12M. The position accounts for ﹤0.01% of the portfolio, ranked #2025.

UBS AM first reported a position in GSK in Q2 2013 and has held it in 23 quarters since. The position peaked at $54.4M in Q4 2019. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • UBS AM held 40,423 shares of GSK worth $2.12M as of Q2 2026.
  • UBS AM left its GSK share count unchanged in Q2 2026.
  • GSK made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2025 holding.
  • UBS AM first reported a position in GSK in Q2 2013 and has held it in 23 quarters since.
  • UBS AM's GSK position peaked at $54.4M in Q4 2019.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.